6 research outputs found
Kaplan-Meier curves for overall survival according to the CTC status using the AdnaTest<sup>®</sup> (A), CellSearch<sup>®</sup> (B), or both assay in combination (C).
<p>Kaplan-Meier curves for overall survival according to the CTC status using the AdnaTest<sup>®</sup> (A), CellSearch<sup>®</sup> (B), or both assay in combination (C).</p
Kaplan-Meier curves for progression-free survival according to the CTC status using the AdnaTest<sup>®</sup> (A), CellSearch<sup>®</sup> (B), or both assay in combination (C).
<p>Kaplan-Meier curves for progression-free survival according to the CTC status using the AdnaTest<sup>®</sup> (A), CellSearch<sup>®</sup> (B), or both assay in combination (C).</p
Detailed patient characteristics and CTC results.
<p>Detailed patient characteristics and CTC results.</p
Additional file 2: Figure S1. of Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer - results from a non-interventional observation study
Progression-free survival; n = number of patients. (PPT 81 kb
Additional file 1: Table S1. of Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer - results from a non-interventional observation study
Mean daily Capecitabine doses (mg/m2) in terms of regimen types. (DOC 30ย�kb